Article Text
Statistics from Altmetric.com
QUESTION: In patients with cancer and venous thromboembolism (VTE), is a fixed dose of subcutaneous low molecular weight (LMW) heparin better than oral warfarin for secondary prophylaxis of VTE?
Design
Randomised {allocation concealed*}†, blinded {outcome assessors and data analysts}†,* controlled trial with primary follow up to 3 months.
Setting
25 centres in France.
Patients
146 patients >18 years of age (mean age 66 y, 55% women) with cancer of any type and deep venous thrombosis and/or pulmonary embolism. Exclusion criteria were previous heparin induced thrombocytopenia, allergy to iodine, pregnancy, fibrinolytic treatment within 3 days, oral anticoagulant use for >5 days, treatment with full dose heparin for this episode of VTE, major pulmonary embolism with shock, life expectancy <3 months, contraindication to anticoagulants, severe hepatic failure, planned major surgery or …